Published in:
18-05-2022 | Radioiodine Therapy | Editorial
To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment
Authors:
Murat Tuncel, Alexis Vrachimis, Alfredo Campenni, Bart de Keizer, Frederik A. Verburg, Michael C. Kreissl, Petra Petranovic Ovcaricek, Tamara Geliashvili, Luca Giovanella
Published in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Issue 10/2022
Login to get access
Excerpt
Recently , Leboulleux et al. published the results of the ESTIMABL 2 trial [
1]. It is an open-label, randomised, phase III trial using a noninferiority comparison design. In this study, included patients were at the lowest-risk end of the low-risk spectrum of differentiated thyroid cancer (DTC) treated with total thyroidectomy with or without lymph node dissection. Patients were randomised to receive low-dose postoperative radioiodine therapy (RAI) with 1.1 GBq in one group and follow-up without RAI in the second group. We congratulate the authors for this work, representing one of the few randomised trials available in the field. However, we would point out some potential limitations that need to be considered before translating these results to generalised clinical recommendations. …